Roche and Alnylam report positive topline results from Phase 2 study KARDIA-1 of zilebesiran
Zilebesiran demonstrated an encouraging safety and tolerability profile in adult patients with mild-to-moderate hypertension
Zilebesiran demonstrated an encouraging safety and tolerability profile in adult patients with mild-to-moderate hypertension
Newcastle University’s Dr Srikanth Ramaswamy has been announced as one of six new Fellows selected for the 2023 Lister prize
The first such initiative under the MoU will involve establishing a Centre of Excellence for Renal Sciences at the Tomo Riba Institute of Health & Medical Sciences (TRIHMS)
The company is already marketing the 4 mg and 10 mg strengths
Survodutide has a novel mechanism of action (agonism of the dual GCG/GLP-1 receptors) that may have direct effects on energy expenditure in the liver in addition to decreasing appetite
Chinook Therapeutics is a clinical-stage biopharmaceutical company with two high-value, late-stage assets in development for IgA nephropathy (IgAN), a rare, progressive chronic kidney disease
Everest and SPH Kyuan will work closely to promote import and channel distribution of XERAVA in China
The company had acquired 26,000 equity shares having face value of Rs. 10 each fully paid up of Eqova
Successes under Ayushman Bharat Digital Health Mission and Pradhan Mantri National Dialysis Programme highlighted
First release of Rs.166 crores incentives under PLI scheme for pharmaceuticals
Subscribe To Our Newsletter & Stay Updated